(function(){ var content_array=["

鍏充簬鎹峰笗鍔�<\/strong>®<\/sup><\/strong>锛堝尮濡ュ竷鏇垮凹锛�<\/strong><\/p> \n

鎹峰笗鍔�®<\/sup>锛堝尮濡ュ竷鏇垮凹锛屽張鍚� LOXO-305锛夋槸涓€绉嶉珮閫夋嫨鎬э紙鍦ㄤ复搴婂墠鐮旂┒涓紝瀵� BTK 鐨勯€夋嫨鎬ф瘮98% 鐨勫叾浠栨縺閰堕珮 300 鍊嶏級銆侀潪鍏变环锛堝彲閫嗭級鐨凚TK鎶戝埗鍓�[6]<\/sup>銆侭TK 鏄粡杩囬獙璇佺殑鍒嗗瓙闈舵爣锛屽湪璁稿 B 缁嗚優鐧借鐥呭拰娣嬪反鐦わ紙鍖呮嫭濂楃粏鑳炴穻宸寸槫锛変腑琚彂鐜�[7],[8]<\/sup>銆�<\/p> \n

鍏充簬濂楃粏鑳炴穻宸寸槫锛�<\/strong>MCL锛�<\/strong><\/p> \n

濂楃粏鑳炴穻宸寸槫锛圡CL锛� 鏄竴绉嶇綍瑙佺殑琛€娑茶偪鐦わ紝涔熸槸闈為湇濂囬噾娣嬪反鐦� (NHL)鐨勪竴绉嶄簹鍨嬨€備腑鍥芥瘡骞村ぇ绾︽瘡50涓囦汉涓湁涓€浜烘偅涓� MCL銆侻CL 婧愯嚜浜� B 娣嬪反缁嗚優锛屾槸涓€绉嶇櫧缁嗚優锛屼篃鏄厤鐤郴缁熺殑涓€閮ㄥ垎銆� MCL 閫氬父鍙戠敓浜庢穻宸寸粨澶栫紭濂楀尯鐨� B 缁嗚優锛岄殢鐫€鑲跨槫鐨勮繘灞曪紝瀹冧細鎵╂暎鍒伴楂撱€佽劸鑴忋€佽倽鑴忔垨娑堝寲閬�[9]<\/sup>銆�<\/p> \n

鍏充簬绀兼潵鍒惰嵂<\/strong><\/p> \n

绀兼潵鍒惰嵂鏄竴瀹惰嚧鍔涗簬閫氳繃绉戝鍒涙柊鏀瑰杽浜虹被鍋ュ悍姘村钩锛屾儬鍙婂叏鐞冩偅鑰呯殑鍖昏嵂鍏徃銆備綔涓哄尰鐤楀仴搴疯涓氱殑棰嗗啗鑰咃紝绀兼潵鍒惰嵂鎷ユ湁杩�150骞寸殑鍘嗗彶銆備粖澶╋紝鎴戜滑鐨勮嵂鐗╁凡甯姪鍏ㄧ悆鏁板崈涓囦汉銆傝繍鐢ㄧ敓鐗╂妧鏈€佸寲瀛﹀拰鍩哄洜鍖诲鐨勫姏閲忥紝鎴戜滑鐨勭瀛﹀姝ｅ湪绉瀬鎺ㄥ姩鏂扮殑鍖诲杩涘睍锛屼互搴斿涓ュ郴鐨勫叏鐞冨仴搴锋寫鎴樸€傞噸鏂板畾涔夌硸灏跨梾涓庤偉鑳栫枟娉曪紝鍑忓皯鑲ヨ儢瀵逛汉浣撶殑闀挎湡褰卞搷锛涘姪鍔涢樋灏旇尐娴烽粯鐥呯殑闃叉不琛屽姩锛涗负涓€绯诲垪濞佽儊浜虹被鍋ュ悍鐨勫厤鐤€х柧鐥呮彁渚涜В鍐虫柟妗堬紱浠ュ強灏嗛毦浠ユ不鎰堢殑鐧岀棁杞彉涓哄彲鎺х殑鐤剧梾銆傜ぜ鏉ュ埗鑽繄鍚戝仴搴蜂笘鐣岀殑姣忎竴姝ワ紝閮芥簮鑷簬鎴戜滑"鑷村姏浜庤鏁扮櫨涓囨偅鑰呯敓娲诲緱鏇寸編濂�"鐨勪俊蹇点€傝繖鍖呮嫭鑷村姏浜庤В鍐冲叏鐞冨閲嶆寫鎴樼殑鍒涙柊涓村簥璇曢獙锛屽悓鏃剁‘淇濊嵂鐗╃殑鍙強鎬у拰鍙礋鎷呮€с€傚鏋滈渶瑕佷簡瑙ｆ洿澶氬叧浜庣ぜ鏉ュ埗鑽殑淇℃伅锛岃鐧诲綍锛歸ww.lilly.com銆�<\/p> \n

\n \n \n \n

[1] Nirav N. S, Wojciech J, Pier Z, et al. Pirtobrutinib in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Mantle Cell Lymphoma (MCL): Updated Results and Subgroup Analysis from the Phase 1\/2 BRUIN Study with 2 Years of Survival Follow-up. Journal of Clinical Oncology, Volume 41, Number 16_suppl. doi: 10.1200\/JCO.2023.41.16_suppl.7514
[2] Michael L. W, Nirav N. S, Wojciech J, et al. Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed \/ Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1\/2 BRUIN Study. Blood (2022) 140 (Supplement 1): 9368鈥�9372. doi: 10.1182\/blood-2022-159425
[3] Yuqin S, Shuhua Y, Haiyan Y et al. Pirtobrutinib, a Non-Covalent (Reversible) BTK Inhibitor in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study. Blood, Volume 142, Supplement 1, 2 November 2023, Page 3636. Doi: 10.1182\/blood-2023-173287
[4] Georg H, Martin D Lucie O, Eva G, et al. Real-world experience among patients with relapsed\/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study. Br J Haematol. 2022 Oct 18;202(4):749鈥�759. doi: 10.1111\/bjh.18519. doi: 10.1111\/bjh.18519
[5] Lisa M. H, Yongmei C, Paolo B. A, et al. Outcomes among Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States: A Real World Electronic Medical Records Study. Adv Hematol. 2022 Dec 28:2022:8262787. doi: 10.1155\/2022\/8262787.
[6] Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397(10277):892-901. doi:10.1016\/S0140-6736(21)00224-5
[7] Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79. Published 2020 Jun 17. doi:10.1186\/s13045-020-00914-1
[8] Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40. Published 2021 Mar 6. doi:10.1186\/s13045-021-01049-7
[9] National Organization for Rare Disorders. Mantle cell lymphoma. Accessed 26 October 2022. https:\/\/rarediseases.org\/rare-diseases\/mantle-cell-lymphoma<\/a><\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n

鑻ヤ綘鎯充簡瑙ｆ洿澶氭湁鍏崇柧鐥呯煡璇嗙殑淇℃伅锛岃鍜ㄨ鍖荤枟鍗敓涓撲笟浜哄＋銆傛湰鍐呭鐢辩ぜ鏉ヤ腑鍥芥彁渚涙敮鎸併€傚鎵瑰彿PP-MG-CN-3724銆�<\/p>"]; $("#dvExtra").html(content_array[0]);})();